Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novavax : India seeks health worker database for possible COVID-19 vaccination

10/23/2020 | 06:00am EST

(Adds details)

MUMBAI/BHUBANESWAR, India, Oct 23 (Reuters) - India is urgently preparing a database of all government and private health personnel to quickly vaccinate them against the novel coronavirus once it is safe to do so, health authorities said on Friday.

Prime Minister Narendra Modi has promised to provide any successful vaccine to each of India's 1.3 billion people, but frontline health workers would be the first to get the shots.

The Ministry of Health and Family Welfare is aiming to vaccinate 200 million to 250 million people by July.

"Vaccine would be supplied by the government of India to all states for free," Pradipta Mohapatra, the top health bureaucrat of Odisha state who attended a video conference with federal health officials, told Reuters.

"First to be vaccinated are the health workers both in government and private sector. The policy is uniform for the whole country."

Mohapatra said states would have to provide details of such workers to the federal government by next Friday.

India has the world's highest vaccine-making capacity and the privately held Serum Institute of India has pledged to make up to 200 million COVID-19 doses for poorer countries, including India, next year. It has contracts to mass-produce vaccine candidates from AstraZeneca Plc and Novavax Inc .

While preparations for a possible vaccine roll-out gather pace, India's recorded rise in infections has slowed since reaching a peak on Sept. 17.

It reported 54,366 new cases in the past 24 hours, taking the total to 7.8 million. It has the second highest number of reported infections after the United States.

On Friday, Modi held his first election rally since the virus took hold in the country in March, drawing thousands of cheering supporters standing shoulder to shoulder and ignoring social distancing rules.

Other politicians including opposition Congress party's Rahul Gandhi also attended big rallies in the eastern state of Bihar, where local elections start in phases from next week. (Reporting by Shilpa Jamkhandikar in Mumbai Editing by Krishna Das and Ana Nicolaci da Costa)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.96% 7958 Delayed Quote.4.61%
NOVAVAX, INC. -2.25% 126.25 Delayed Quote.3,145.23%
All news about NOVAVAX, INC.
12/02North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
12/02North Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
12/01AstraZeneca partner sticks with two full dose regimen in COVID trials in Indi..
11/30Nikola, JetBlue fall; Moderna, Novavax rise
11/30Novavax expects delayed U.S. COVID-19 vaccine trial to start in coming weeks
11/30NOVAVAX : Announces COVID-19 Vaccine Clinical Development Progress
11/30Novavax delays U.S. COVID-19 vaccine trial again, now sees start in the comin..
11/30NOVAVAX : Announces COVID-19 Vaccine Clinical Development Progress
11/30Novavax Announces COVID-19 Vaccine Clinical Development Progress
More news
Financials (USD)
Sales 2020 550 M - -
Net income 2020 -310 M - -
Net cash 2020 465 M - -
P/E ratio 2020 -23,9x
Yield 2020 -
Capitalization 6 605 M 6 605 M -
EV / Sales 2020 11,2x
EV / Sales 2021 1,87x
Nbr of Employees 522
Free-Float 97,6%
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 186,20 $
Last Close Price 129,16 $
Spread / Highest target 72,7%
Spread / Average Target 44,2%
Spread / Lowest Target -41,9%
EPS Revisions
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Gregory F. Covino Chief Financial Officer & Executive Vice President
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.3,052.76%6 605
MODERNA, INC.705.88%62 229
LONZA GROUP AG52.83%45 010
CELLTRION, INC.109.94%42 993
SEAGEN INC.57.68%32 484